Open AccessRifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection
Author(s) -
Marc Weiner,
Radojka M. Savić,
William R. Mac Kenzie,
Diane Wing,
Charles A. Peloquin,
Melissa Engle,
Erin E. Bliven,
Thomas J. Prihoda,
Jonathan Gelfond,
Nigel Scott,
Susan M. AbdelRahman,
Gregory L. Kearns,
William J. Burman,
Timothy R. Sterling,
Margarita E. Villarino
Publication year - 2014
Publication title -
journal of the pediatric infectious diseases society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 31
eISSN - 2048-7207
pISSN - 2048-7193
DOI - 10.1093/jpids/pit077
Subject(s) - rifapentine , medicine , tolerability , pharmacokinetics , rifamycin , isoniazid , dosing , tuberculosis , pharmacodynamics , latent tuberculosis , pharmacology , adverse effect , antibiotics , mycobacterium tuberculosis , pathology , microbiology and biotechnology , biology
In a phase 3, randomized clinical trial (PREVENT TB) of 8053 people with latent tuberculosis infection, 12 once-weekly doses of rifapentine and isoniazid had good efficacy and tolerability. Children received higher rifapentine milligram per kilogram doses than adults. In the present pharmacokinetic study (a component of the PREVENT TB trial), rifapentine exposure was compared between children and adults.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom